News

Eyesafe Reinvents Blue Light Glasses: 2X Protection for Eyes and Sleep & New Requirements for Blue Light Eyewear

Developed in collaboration with top ophthalmologists and optometrists, Eyesafe® Eyewear features advanced lens technology by BluTech, designed to reduce eye…

10 months ago

ADIA Nutrition Proudly Launches Adia Labs LLC and Begins Sales of Branded Stem Cell Products

Winter Park, Florida--(Newsfile Corp. - February 20, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare and…

10 months ago

Ezra Announces New FDA Clearance, Enhancing the Capabilities of Its Full-Body Scan Technology

The latest clearance enables new, faster scan options for more patientsNEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ezra, the…

10 months ago

COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain…

10 months ago

Precision Optics Announces Pricing of $5.1 Million Offering of Common Stock to Fund Business Expansion

GARDNER, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of…

10 months ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity…

10 months ago

HWH International Inc. Announces Reverse Stock Split

BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the “Company”) (NASDAQ: HWH), a purpose-driven lifestyle company, today…

10 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax…

10 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate…

10 months ago

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic…

10 months ago